People channel feed

Caris­ma to lay off staff, drop clin­i­cal CAR-M pro­gram in fa­vor of sec­ond can­di­date

Last year
R&D
Cell/Gene Tx

Q&A: In­sitro CEO Daphne Koller on ‘po­ten­tial­ly de­struc­tive’ AI hype, Nvidi­a's chips, and biotech's da­ta prob­lem

Last year
R&D

Bris­tol My­ers to con­duct lay­offs at Mi­rati fa­cil­i­ty in Cal­i­for­nia

Last year

Lead House spon­sor of WuXi-linked bill to leave Con­gress ear­ly

Last year
China
Pharma

Why Lenz picked a re­verse merg­er in­stead of an IPO: Q&A

Last year
Financing

Seagen’s for­mer com­mer­cial chief joins the board at health­care agency minds + as­sem­bly

Last year
Pharma
Marketing

GSK to part ways with 'most' Bel­lus Health em­ploy­ees a year af­ter $2B buy

Last year
Pharma

Parex­el CEO to re­tire; CAR-T mak­er Affy­Im­mune pro­motes busi­ness leader to chief ex­ec­u­tive

Last year
Peer Review

Bay­er's re­struc­tur­ing hits phar­ma lead­er­ship, shift­ing about half of ex­ecs off top team

Last year
Pharma

As fo­cus shifts to on­col­o­gy, BioN­Tech nabs No­var­tis ex­ec as chief com­mer­cial of­fi­cer

Last year
R&D

Bio­gen los­es CMO, neu­ro­mus­cu­lar leader; John Hood adds pres­i­dent, CFO at En­deav­or Bio­Med­i­cines

Last year
Peer Review

Co­herus' new fo­cus on on­col­o­gy leads to re­struc­tur­ing, 30% lay­offs

Last year

Fe­male in­vestors track progress, call for more women on boards and in lead­er­ship roles

Last year
Financing
In Focus

Spruce Bio­sciences’ stock plum­mets in wake of PhI­Ib flop, biotech to cut staff

Last year
R&D

Sanofi to shut­ter ex-Kymab R&D fa­cil­i­ty in the UK

Last year
R&D

Ex-The­seus ex­ecs ex­tend GIST mis­sion by tak­ing helm of IDRx

Last year

Eye­Point poach­es med­ical chief from Apel­lis; San­doz CFO, long­time BioN­Tech ex­ec to re­tire

Last year
Peer Review

Kro­nos Bio cuts a fifth of staff, ex­plores new dos­ing sched­ule for sol­id tu­mor drug

Last year
R&D

Sum­it­o­mo to lay off about 400 em­ploy­ees, reshuf­fle ex­ecs in North Amer­i­ca as sales dis­ap­points

Last year

Q&A: Ken Song de­tails Rayze­Bio’s path from Se­ries A to IPO in 3 years, tak­ing a down round and be­ing dis­ci­plined

Last year

Who’s paving the way for LGBTQ+ lead­ers in bio­phar­ma? Nom­i­nate them for End­points’ an­nu­al re­port

Last year

Al­ly Bridge beefs up 'new gen­er­a­tion' as in­vest­ment firm pass­es 10-year mark

Last year
Financing

Ar­rakis Ther­a­peu­tics re­duces head­count by 20%

Last year
Startups

Mod­er­na lays off man­u­fac­tur­ing work­ers in Mass­a­chu­setts to 're­size' Covid-19 foot­print

Last year
Manufacturing
First page Previous page 12131415161718 Next page Last page
A service from the Financial Times